Brief: BerGenBio Presents Phase II Bemcentinib Combination Study In NSCLC At Annual SITC Meeting

Oncoinvent ASA

11/11/2020 13:03

Nov 11 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY
IN
NSCLC AT ANNUAL SITC MEETING
    * FINDINGS SUGGEST BEMCENTINIB HAS POTENTIAL TO REVERSE
ACQUIRED
RESISTANCE TO CHECKPOINT INHIBITORS AMONG PREV TREATED NSCLC
PATIENTS BY TARGETING AXL EXPRESSING MACROPHAGES AND REGULATORY
DENDRITIC CELLS
    * STUDY DEMONSTRATED A MEDIAN PROGRESSION-FREE SURVIVAL
AMONG CAXL
POSITIVE PATIENTS IN COHORT B PATIENTS OF 4.73 MONTHS, COMPARED
WITH 1.87 MONTHS AMONG CAXL-NEGATIVE PATIENTS
    * COMBINATION OF BEMCENTINIB AND PEMBROLIZUMAB WAS OVERALL
SHOWN
TO BE WELL TOLERATED AND CLINICALLY ACTIVE IN CPI-REFRACTORY
COMPOSITE AXL (CAXL) POSITIVE NSCLC

Source text for Eikon:  ID:nWkr3BVP4h 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))